Clinical trials: Lenvatinib Treatment
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC)
- Trial name
- NCT03867370
- Testing
- Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Clear Cell Renal Cell Carcinoma
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Cadonilimab and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for…
- Trial name
- NCT06138496
- Testing
- Cadonilimab Combined With Lenvatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Rectal Adenocarcinoma
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and…
- Trial name
- NCT02935309
- Testing
- Lenvatinib, Capecitabine, External Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cholangiocarcinoma, Intrahepatic
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative…
- Trial name
- NCT04506281
- Testing
- neoadjuvant treatment
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects with resectable hepatocellular carcinoma…
- Trial name
- NeoLeap-HCC (NCT05389527)
- Testing
- Pembrolizumab+Lenvatinib
- Where
- 4 sites in China
- Volunteers
- 43 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial
Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.
- Conditions
- Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma, Digestive System Neoplasms
- Trial name
- NCT06794073
- Testing
- Multimodal Thermal Therapy
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Zhongshan Hospital
Head and Neck Mucosal Melanomas
A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)
This study aims to conduct a prospective clinical trial investigating the use of pucotenlimab in combination with lenvatinib and temozolomide as neoadjuvant and postoperative adjuvant therapy for resectable oral and head and neck…
- Trial name
- NCT07353073
- Testing
- Preoperatively, patients will receive 2 cycles of pucotenlimab (200 mg every 3 weeks, or 3 mg/kg every 3 weeks) combined with lenvatinib (20 mg once daily) and temozolomide (150 mg/m² orally once dail
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Hepatocellular Carcinoma
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
Abdominal lymph node metastasis (LNM) is one of the major modes of extrahepatic metastasis in hepatocellular carcinoma (HCC). Immunotherapy targeting the PD-1/PD-L1 checkpoints combined with targeted therapy is the standard…
- Trial name
- HSBRT2401 (NCT06261125)
- Testing
- Stereotactic body radiotherapy, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Mian XI
Urologic Neoplasms
A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma
Study Design Prospective, single-arm, multicenter clinical study. Study Drugs Neoadjuvant phase: QL1706 (Aipaluo Tuoworilimab, an anti-PD-1/CTLA-4 combination antibody) plus lenvatinib. Adjuvant phase: QL1706 monotherapy.
- Trial name
- NCT07741617
- Testing
- Iparomlimab and Tuvonralimab in combination with Lenvatinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatocellular Carcinoma
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
The investigators design a phase II clinical study to explore the efficacy and safety of Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in patients with Unresectable, non-metastatic hepatocellular…
- Trial name
- NCT05903456
- Testing
- TACE（transcatheter arterial chemoembolization）, lenvatinib, Icaritin soft capsules
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Squamous Cell, Anorectal Cancer
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
- Trial name
- NCT06669572
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Biliary Tract Cancer (BTC)
Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen
- Trial name
- PILOT-BTC (NCT07159204)
- Testing
- Paclitaxel polymer micelle immunocombination
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who…
- Trial name
- NCT06361758
- Testing
- Cadonilimab+Lenvatinib
- Where
- 3 sites in China
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable Hepatocellular Carcinoma
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with…
- Trial name
- IMbrave251 (NCT04770896)
- Testing
- Atezolizumab, Lenvatinib, Sorafenib
- Where
- 124 sites in Austria, Belgium and 26 more
- Volunteers
- 557 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus…
- Trial name
- LEAF-01 (NCT07047586)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of…
- Trial name
- NCT03713593
- Testing
- lenvatinib, pembrolizumab
- Where
- 172 sites in United States, Australia and 19 more
- Volunteers
- 794 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC)
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor…
- Trial name
- NCT06746961
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib
- Volunteers
- 49 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Cancer
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line treatment for advanced gastric cancer or…
- Trial name
- NCT06157996
- Testing
- lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
This prospective, single-arm study was aimed to evaluate the efficacy of recombinant human adenovirus type 5 injection combined with tislelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06253598
- Testing
- Recombinant Human Adenovirus Type 5, Lenvatinib, Tislelizumab
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Unresectable Hepatocellular Carcinoma
Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer
This study reviewed real-world outcomes of patients with unresectable hepatocellular carcinoma who received lenvatinib-based treatment.
- Trial name
- NCT07298538
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital